AstraZeneca (LON:AZN)‘s stock had its “sell” rating reaffirmed by analysts at UBS Group in a report issued on Monday, Borsen Zeitung reports. They currently have a GBX 5,800 ($76.30) target price on the biopharmaceutical company’s stock. UBS Group’s price objective would indicate a potential downside of 19.96% from the stock’s previous close.
A number of other equities analysts have also issued reports on the stock. Liberum Capital boosted their target price on shares of AstraZeneca from GBX 8,250 ($108.52) to GBX 8,300 ($109.18) and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Jefferies Financial Group reiterated a “hold” rating and set a GBX 6,700 ($88.13) price target on shares of AstraZeneca in a research note on Monday, November 11th. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, December 5th. Finally, Bryan, Garnier & Co upgraded shares of AstraZeneca to a “buy” rating and lifted their price target for the stock from GBX 7,700 ($101.29) to GBX 7,950 ($104.58) in a research note on Monday, November 25th. Three analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of GBX 7,585.67 ($99.79).
Shares of AZN stock opened at GBX 7,246 ($95.32) on Monday. AstraZeneca has a 1 year low of GBX 109.51 ($1.44) and a 1 year high of GBX 8,227.88 ($108.23). The firm’s fifty day simple moving average is GBX 7,335.76 and its 200 day simple moving average is GBX 6,880.46. The firm has a market capitalization of $95.06 billion and a P/E ratio of 45.46. The company has a current ratio of 0.92, a quick ratio of 0.70 and a debt-to-equity ratio of 148.59.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What is a Swap?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.